<p>美國市場在過去一週保持平穩，但在過去 12 個月中經歷了顯著的 28% 增長，預計年收益將增長 16%。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為這通常表明那些最瞭解業務的人對其有強烈的信心。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們篩選的 193 只內部持股比例高的快速成長美國公司的完整名單。</p>
<p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
<h2>Enovix (ENVX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Enovix Corporation 設計、開發並製造鋰離子電池單元，業務遍及美國及國際市場，市值為 14.4 億美元。</p>
<p><strong>運營：</strong> 公司的收入部分來自其電池/電池系統部門，收入為 3182 萬美元。</p>
<p><strong>內部持股比例：</strong> 12.4%</p>
<p>Enovix 的交易價格顯著低於其估計的公允價值，且增長前景強勁。預計其收入將以每年 36.3% 的速度增長，超過美國市場的平均水平。預計該公司將在三年內實現盈利，年收益增長 41.13%。最近的財務結果顯示，銷售額有所改善，淨虧損較去年減少，儘管近期內部交易活動保持不變。Enovix 已完成股票回購計劃，併為與員工持股計劃相關的 6500 萬美元普通股發行提交了貨架註冊。</p>
<ul>
<li>點擊這裏瞭解 Enovix 的細節，查看我們的詳細分析未來增長報告。</li>
<li>我們的估值報告顯示 Enovix 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown"/></p>
<p>截至 2026 年 5 月的 ENVX 持股結構</p>
<h2>ImmunityBio (IBRX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ImmunityBio, Inc. 是一家生物技術公司，致力於開發和商業化下一代免疫療法，旨在激活免疫系統以提供對癌症和傳染病的長期保護，市值約為 73.4 億美元。</p>
<p><strong>運營：</strong> 公司的收入部分主要集中在開發下一代療法，收入為 1.1329 億美元。</p>
<p><strong>內部持股比例：</strong> 28.6%</p>
<p>ImmunityBio 正在經歷強勁的增長，預計其收入將以每年 52% 的速度增長，超過美國市場的平均水平。儘管近期股東稀釋和股價波動較大，但預計該公司將在三年內實現盈利。最近在沙特阿拉伯和其他地區對 ANKTIVA 的產品批准突顯了其全球擴展的存在。然而，法律挑戰和對促銷行為的監管審查仍然存在風險。公司的現金流持續時間不足一年，需要謹慎的財務管理。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 ImmunityBio 的表現。</li>
<li>我們編制的估值報告表明 ImmunityBio 當前的價格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月的 IBRX 收益和收入增長</p>
<h2>Wealthfront (WLTH)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Wealthfront Corporation 是一傢俬營投資管理公司，市值為 16.2 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其資產管理部門產生收入，收入為 3.65 億美元。</p>
<p><strong>內部持股比例：</strong> 14.2%</p>
<p>Wealthfront Corporation 最近被納入多個 Russell 指數，突顯其作為成長實體的認可，儘管其財務狀況呈現出混合的局面。該公司的收入在 2026 年第四季度上升至 9614 萬美元，但與去年盈利相比，淨虧損為 1.3366 億美元。儘管如此，Wealthfront 預計將在三年內實現盈利，並已啓動一項 1 億美元的股票回購計劃，顯示出對未來前景的信心，內部持股比例也較高。</p>
<ul>
<li>在這份增長報告中解鎖我們對 Wealthfront 股票分析的全面見解。</li>
<li>在審查我們的最新估值報告後，Wealthfront 的股價可能過於樂觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月的 WLTH 收益和收入增長</p>
<h2>下一步</h2>
<ul>
<li>點擊這裏更仔細地查看我們篩選的 193 家內部持股比例高的快速成長美國公司名單。</li>
<li>尋找新視角？癌症的終結？這 31 只新興的人工智能股票正在開發技術，以便早期識別癌症和阿爾茨海默病等改變生活的疾病。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<h3><strong>新功能：</strong> AI 股票篩選器與提醒</h3>
<p>我們的新 AI 股票篩選器每天掃描市場，以發現機會。</p>
<p>• 分紅強勁的股票（收益率 3% 以上）</p>
<p>• 內部人士買入的被低估小盤股</p>
<p>• 高增長的科技和 AI 公司</p>
<p>或者從 50 多個指標中構建您自己的篩選器。</p>
<p>立即免費探索</p>

ENVX

IBRX

優信

<p>美國市場在過去一年中上漲了 28%，預計年收益將增長 16%。高內部持股的成長型公司受到關注，包括優信（35.7% 的持股比例，74.1% 的收益增長）和 ImmunityBio（28.6% 的持股比例，52% 的收益增長）。Enovix 和 Wealthfront 也因其增長潛力而受到關注，儘管面臨挑戰。文章強調了內部持股作為信心指標的重要性，並提供了對這些公司的財務健康狀況和未來前景的見解</p>

<p>The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.</p>
<div class="lb-trans"><p>美國市場在過去一週保持平穩，但在過去 12 個月中經歷了顯著的 28% 增長，預計年收益將增長 16%。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為這通常表明那些最瞭解業務的人對其有強烈的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>優信 (UXIN)</td>
<td>35.7%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>12.8%</td>
<td>53.8%</td>
</tr>
<tr>
<td>Precigen (PGEN)</td>
<td>11.9%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17%</td>
<td>53.2%</td>
</tr>
<tr>
<td>Enovix (ENVX)</td>
<td>12.4%</td>
<td>41.1%</td>
</tr>
<tr>
<td>Clene (CLNN)</td>
<td>12%</td>
<td>62.2%</td>
</tr>
<tr>
<td>Caledonia Mining (CMCL)</td>
<td>14.1%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Better Home &amp; Finance Holding (BETR)</td>
<td>19.3%</td>
<td>100.6%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.8%</td>
<td>27.8%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>22.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 193 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們篩選的 193 只內部持股比例高的快速成長美國公司的完整名單。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
</div><h2>Enovix (ENVX)</h2>
<div class="lb-trans"><h2>Enovix (ENVX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Enovix Corporation designs, develops, and manufactures lithium-ion battery cells both in the United States and internationally, with a market cap of $1.44 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Enovix Corporation 設計、開發並製造鋰離子電池單元，業務遍及美國及國際市場，市值為 14.4 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment consists of $31.82 million from its Batteries / Battery Systems division.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分來自其電池/電池系統部門，收入為 3182 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 12.4%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 12.4%</p>
</div><p>Enovix is trading significantly below its estimated fair value, with strong growth prospects. Its revenue is expected to grow at 36.3% per year, surpassing the US market average. The company is forecasted to become profitable within three years, with earnings growing at 41.13% annually. Recent financial results show improved sales and reduced net losses compared to the previous year, although insider trading activity remains unchanged recently. Enovix has completed a share buyback program and filed a shelf registration for $65 million in common stock offerings related to an ESOP initiative.</p>
<div class="lb-trans"><p>Enovix 的交易價格顯著低於其估計的公允價值，且增長前景強勁。預計其收入將以每年 36.3% 的速度增長，超過美國市場的平均水平。預計該公司將在三年內實現盈利，年收益增長 41.13%。最近的財務結果顯示，銷售額有所改善，淨虧損較去年減少，儘管近期內部交易活動保持不變。Enovix 已完成股票回購計劃，併為與員工持股計劃相關的 6500 萬美元普通股發行提交了貨架註冊。</p>
</div><ul>
<li>Click here to discover the nuances of Enovix with our detailed analytical future growth report.</li>
<li>Our valuation report here indicates Enovix may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Enovix 的細節，查看我們的詳細分析未來增長報告。</li>
<li>我們的估值報告顯示 Enovix 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/2288607e-d696-483f-841e-c24939229c74/chart/ownership-breakdown"/></p>
<p>ENVX Ownership Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 ENVX 持股結構</p>
</div><h2>ImmunityBio (IBRX)</h2>
<div class="lb-trans"><h2>ImmunityBio (IBRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing next-generation immunotherapies aimed at activating the immune system for long-lasting protection against cancer and infectious diseases, with a market cap of approximately $7.34 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ImmunityBio, Inc. 是一家生物技術公司，致力於開發和商業化下一代免疫療法，旨在激活免疫系統以提供對癌症和傳染病的長期保護，市值約為 73.4 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment is primarily focused on developing next-generation therapies, generating $113.29 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分主要集中在開發下一代療法，收入為 1.1329 億美元。</p>
</div><p><strong>Insider Ownership:</strong> 28.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 28.6%</p>
</div><p>ImmunityBio is experiencing robust growth, with revenue forecasted to increase by 52% annually, outpacing the US market's average. Despite recent shareholder dilution and highly volatile share prices, the company is expected to achieve profitability within three years. Recent product approvals in Saudi Arabia and other regions for ANKTIVA highlight its expanding global presence. However, legal challenges and regulatory scrutiny over promotional practices present ongoing risks. The company's cash runway remains limited to less than a year, necessitating careful financial management.</p>
<div class="lb-trans"><p>ImmunityBio 正在經歷強勁的增長，預計其收入將以每年 52% 的速度增長，超過美國市場的平均水平。儘管近期股東稀釋和股價波動較大，但預計該公司將在三年內實現盈利。最近在沙特阿拉伯和其他地區對 ANKTIVA 的產品批准突顯了其全球擴展的存在。然而，法律挑戰和對促銷行為的監管審查仍然存在風險。公司的現金流持續時間不足一年，需要謹慎的財務管理。</p>
</div><ul>
<li>Get an in-depth perspective on ImmunityBio's performance by reading our analyst estimates report here.</li>
<li>The valuation report we've compiled suggests that ImmunityBio's current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 ImmunityBio 的表現。</li>
<li>我們編制的估值報告表明 ImmunityBio 當前的價格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>IBRX Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 IBRX 收益和收入增長</p>
</div><h2>Wealthfront (WLTH)</h2>
<div class="lb-trans"><h2>Wealthfront (WLTH)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Wealthfront Corporation is a privately owned investment manager with a market cap of $1.62 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Wealthfront Corporation 是一傢俬營投資管理公司，市值為 16.2 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its asset management segment, which accounts for $365 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其資產管理部門產生收入，收入為 3.65 億美元。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 14.2%</p>
</div><p>Wealthfront Corporation's recent inclusion in multiple Russell indices underscores its recognition as a growth entity, though its financials present a mixed picture. The company's revenue rose to US$96.14 million in Q4 2026, yet it recorded a net loss of US$133.66 million compared to the previous year's profit. Despite this, Wealthfront is projected to achieve profitability within three years and has initiated a US$100 million share buyback program, signaling confidence in future prospects amidst high insider ownership levels.</p>
<div class="lb-trans"><p>Wealthfront Corporation 最近被納入多個 Russell 指數，突顯其作為成長實體的認可，儘管其財務狀況呈現出混合的局面。該公司的收入在 2026 年第四季度上升至 9614 萬美元，但與去年盈利相比，淨虧損為 1.3366 億美元。儘管如此，Wealthfront 預計將在三年內實現盈利，並已啓動一項 1 億美元的股票回購計劃，顯示出對未來前景的信心，內部持股比例也較高。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Wealthfront stock in this growth report.</li>
<li>Upon reviewing our latest valuation report, Wealthfront's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份增長報告中解鎖我們對 Wealthfront 股票分析的全面見解。</li>
<li>在審查我們的最新估值報告後，Wealthfront 的股價可能過於樂觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/a7233899-c2f2-42e7-9e52-c388a7265b04/chart/earnings-and-revenue-growth"/></p>
<p>WLTH Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 WLTH 收益和收入增長</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Take a closer look at our Fast Growing US Companies With High Insider Ownership list of 193 companies by clicking here.</li>
<li>Searching for a Fresh Perspective? The end of cancer? These 31 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏更仔細地查看我們篩選的 193 家內部持股比例高的快速成長美國公司名單。</li>
<li>尋找新視角？癌症的終結？這 31 只新興的人工智能股票正在開發技術，以便早期識別癌症和阿爾茨海默病等改變生活的疾病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票篩選器與提醒</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新 AI 股票篩選器每天掃描市場，以發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分紅強勁的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士買入的被低估小盤股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者從 50 多個指標中構建您自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

2026 年 5 月值得關注的高內部持股增長的股票